Streetbeat News

Revenues

INLX

Intellinetics has reiterated its FY23 guidance, stating that it expects to grow its revenues and adjusted EBITDA on a year-on-year basis.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:26 pm

CURI

CuriosityStream has projected its Q3 revenue to be between $13.5M and $15.5M, with an estimate of $14.36M.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:25 pm

UGRO

urban-gro has revised its FY23 consolidated revenue forecast from $100M-$120M to $90M-$95M, lower than the estimated $103M. This is due to the pause of an active project and timing shifts in other projects. The company expects sequential quarterly increases in both revenue and Adjusted EBITDA.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:23 pm

NVTS

Navitas Semiconductor has projected its Q3 net revenues to reach $21M, plus or minus 2%, which is higher than the consensus estimate of $20.08M.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:20 pm

DLPN

Dolphin Entertainment expects to deliver strong, double-digit annual revenue growth in the second half of the year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:15 pm

NOGN

Nogin reported worse-than-expected Q2 financial results and issued FY23 revenue guidance below estimates, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:15 pm

PPSI

Pioneer Power Solutions has reiterated its FY23 revenue guidance of $42M-$45M, which is higher than the estimated $41.26M.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:14 pm

NOGN

Nogin has projected its FY23 revenue to be between $50M-$55M, which is significantly lower than the estimated $79.24M.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:08 pm

SLGC

SomaLogic has provided its financial guidance for FY23, expecting its revenue to range between $80M and $84M. This is in comparison to the estimated $81.62M.

Portfolio Pulse from Happy Mohamed

August 14, 2023 | 8:08 pm

JAZZ

Cantor Fitzgerald analyst Charles C. Duncan has reiterated an Overweight rating on Jazz Pharmaceuticals Plc (NASDAQ:JAZZ), but lowered the price target from $210 to $180 due to a new valuation methodology and a higher cost of capital assumption. Duncan also lowered the FY23 and FY24 EPS estimates significantly. However, he praised Jazz's Q2 2023 total revenues of $957.3 million, which exceeded estimates, and the company's progress in its commercial portfolio. The analyst also highlighted the potential of Jazz's Xywav and Epidiolex drugs.

Portfolio Pulse from Nabaparna Bhattacharya

August 14, 2023 | 7:25 pm